9 Signs Your IGF-1 Is Too High (And What to Do Before Your Next Injection)

Carpal tunnel that appeared six weeks after starting your ipamorelin stack is not a coincidence. Neither is the joint pain in three different locations, or the reason your rings feel tight in the morning even though your diet has not changed. GH-excess symptoms creep in gradually and every one of them looks like something else. The 2024 Pituitary consensus guidelines noted the average time from first symptom to clinical diagnosis of GH excess is 7 to 8 years. That delay is not because the signs are rare. It is because each sign, in isolation, reads as entirely normal.

This article gives you a checklist built from clinical acromegaly cohort data and from GH secretagogue RCTs where adverse events were systematically tracked. Not all nine signs appear at once. Most users with mildly elevated IGF-1 present with two to four. But any single sign from this list, appearing within weeks of starting or increasing a GH peptide protocol, should pause your next injection until you have a blood draw.

What Does It Feel Like When IGF-1 Is Too High?

Signs one through four are the most common and most actionable. Signs five through nine are less universal but still clinically documented. Work through the list systematically, not selectively.

1. Joint Pain That Migrates Between Multiple Sites

Arthralgia was the most common symptom in the largest acromegaly cohort ever compiled, appearing in 52.8% of GH-excess patients in Melmed's 2009 review in the Endocrinology and Metabolism Clinics of North America. The distinctive pattern is multiple large joints at once, with pain that shifts between sites. Knees, hips, shoulders, and wrists are most common.

This is not the same as DOMS from training. Training soreness has a clear cause, peaks 24 to 48 hours after the session, and resolves. GH-excess arthralgia tends to be worst in the morning, improves slightly with movement, and does not correspond to workout load. If you ache in three different joints on a day you did not train, and this started after beginning a protocol, do not chalk it up to overtraining.

2. Bilateral Carpal Tunnel or Tingling in Both Hands

Carpal tunnel syndrome appeared in 30 to 50% of GH-excess patients in the same cohort review, and the bilateral presentation is the diagnostic tell. Ergonomic carpal tunnel is almost always unilateral. It develops in the dominant hand from sustained repetitive strain. When both hands develop tingling or numbness within weeks of starting a peptide protocol, the cause is soft-tissue edema compressing the median nerve in the carpal tunnel, not mechanical strain.

The early presentation is typically tingling or a pins-and-needles sensation in the thumb, index finger, and middle finger, often waking you at night. If you are shaking your hands out upon waking and this is new, and you are on an ipamorelin or CJC-1295 stack, this is a first-tier signal. Do not wait for it to progress before drawing blood.

3. Morning Puffiness: Tight Rings, Swollen Fingers, or a Puffy Face

GH directly promotes sodium and water retention at the renal tubule. The result is increased extracellular fluid that appears as soft-tissue edema: rings that feel tighter in the morning, a face that looks fuller, or feet that swell by end of day. Your weight on the scale may not change much, but the distribution shifts toward more fluid in soft tissue.

Mild soft-tissue swelling at the start of a protocol is normal and often resolves within the first four weeks as the body adapts. Persistent or worsening edema beyond week four to six at a stable dose is the signal, not the initial presentation. The test: does the swelling resolve on rest days or during a two-day protocol pause? If not, it is not adaptation. It is sustained IGF-1 activity your tissues cannot fully buffer.

4. Fasting Glucose Looks Fine -- But Your Glucose Tolerance Is Already Impaired

This finding will make you want to pause and re-read it. In a 1998 JCEM clinical trial of MK-677 in adults, fasting blood glucose and fasting insulin were essentially unchanged after two months of use. Everything looked normal on a standard fasting panel. But when the same researchers ran oral glucose tolerance tests on the same subjects, significant glucose impairment appeared at both the two-week and eight-week marks.

"Oral glucose tolerance was significantly impaired at 2 and 8 weeks of MK-677 treatment despite no significant changes in fasting glucose or fasting insulin concentrations."

Murphy MG et al., Journal of Clinical Endocrinology and Metabolism, 1998

A standard fasting panel will miss early glucose handling problems from elevated IGF-1. Your fasting glucose might read 88 mg/dL while your two-hour glucose response has already shifted. The practical early signals are behavioral: fasting glucose that was previously stable now running 5 to 10 mg/dL higher than your pre-protocol baseline, afternoon carbohydrate cravings that were not there before, or energy crashes two hours after a normal-sized meal. These patterns can precede any change in fasting labs by weeks.

5. Unexpected Sweating at Rest or Night Sweats

Hyperhidrosis (sweating beyond what your activity warrants) is described as near-universal in GH-excess literature. Oily skin, new acne appearing in adulthood, and noticeably increased sweating during sleep or at rest are consistent early features. The mechanism is direct GH stimulation of eccrine and sebaceous glands. It is not driven by higher metabolic rate or training intensity.

The distinguishing feature: the sweating appears at rest and especially at night, not primarily during exertion. If you have started waking up damp without an obvious explanation (room temperature, illness, alcohol), and this started after beginning or increasing a GH peptide protocol, note it and add it to your tally of potential signs.

6. New or Worsened Snoring or Unrefreshing Sleep

Sleep apnea appeared in 43% of GH-excess patients in a 2022 JCEM respiratory cohort study. The mechanism is soft-tissue growth in the upper airway: tongue, pharyngeal walls, and soft palate tissue that narrows the passage during sleep. You do not need structural acromegalic changes for this to begin. Mild soft-tissue edema throughout the airway, driven by sodium retention and IGF-1-mediated tissue growth, can produce functional narrowing.

If a bed partner reports new snoring, or if you are sleeping eight hours and waking exhausted, and this began after starting a protocol, it deserves investigation rather than acceptance. A GH peptide protocol that is actively degrading your sleep quality is not delivering a net benefit, regardless of what it is doing to your IGF-1 number.

7. Fatigue That Coffee Cannot Fix

Fatigue appeared in 49% of GH-excess patients in the same 2022 cohort, and it behaves differently from ordinary tiredness. It does not resolve with more sleep. It often co-occurs with the sleep disruption described in sign six, but it appears independently as well. The paradox is well-documented: low GH causes fatigue, but GH excess causes it too, through different mechanisms involving altered glucose metabolism, inflammatory signaling, and sleep architecture disruption.

If you started a protocol expecting more energy and instead feel chronically drained, and this appeared within four to eight weeks of starting or increasing dose, consider IGF-1 elevation before adjusting your nutrition, sleep hygiene, or training. Protocol fatigue that resolves when you reduce the dose or take a week off is a useful retrospective signal that the dose was too high.

8. New Skin Tags Appearing in Adulthood

Skin tags (acrochordons) are associated with insulin resistance and IGF-1-mediated soft-tissue overgrowth. They appear in friction areas: neck, armpits, groin. A single skin tag is not meaningful. Multiple new skin tags appearing in adulthood, during a period when you are running a GH peptide protocol, is a dermatological signal that is easy to ignore but worth noting.

On its own, this sign would not warrant holding an injection. But if it appears alongside two or more of the signs above, the combined picture warrants a bloodwork review before continuing at the same dose. Treat it as a background signal, not a standalone alarm.

9. IGF-1 Consistently at the Top of Your Age-Matched Range on Two Draws

This is the sign that only shows up on a lab report, but it belongs on this list because it is actionable before symptoms develop. The Endocrine Society and AACE guidelines are consistent on this point: the goal of GH therapy is IGF-1 at the midpoint of the age-adjusted normal range, not the top. An IGF-1 that reads in the 80th percentile or above for your age on two consecutive draws four weeks apart is a dose-reduction signal, even if you feel completely fine and the number is technically within range.

The 2024 Pituitary consensus guidelines define biochemical control of GH excess as an age-adjusted IGF-1 within the normal range. The goal is mid-range maintenance, not "technically not elevated." Persistently high-normal IGF-1 is your pre-symptomatic window. It is the window to act in, not to wait out. See the IGF-1 blood test timing guide to confirm your draw timing is accurate before acting on the number.

What to Do When You Spot One of These Signs

The action steps are the same regardless of which sign you identified. Here is the sequence.

The dose-reduction guidance follows the protocol used in tesamorelin clinical trials (the only FDA-approved GH peptide for adults) and the Endocrine Society's adult GH deficiency treatment guidelines. The clinical standard: confirmed IGF-1 above the age-adjusted upper limit on one draw triggers a 15 to 20% dose reduction with a recheck in four weeks. Two consecutive draws above the upper limit at a reduced dose triggers further reduction or discontinuation. This framework applies to off-label GH secretagogues (ipamorelin, CJC-1295, MK-677) in the absence of a compound-specific monitoring protocol.

How Quickly Do Symptoms Resolve After Reducing the Dose?

The timeline varies by symptom type. Fluid retention, morning puffiness, and soft-tissue swelling typically begin improving within one to two weeks of dose reduction as IGF-1 comes down and renal sodium handling normalizes. Carpal tunnel symptoms can take four to eight weeks to fully resolve even after IGF-1 normalizes because nerve-compression symptoms lag behind the underlying edema. Fatigue and sleep quality often improve faster, typically within two to three weeks.

Joint pain is the slowest to resolve. Soft-tissue changes in joint structures can take six to twelve weeks to return to baseline after dose correction, particularly in people who were running elevated IGF-1 for an extended period. The earlier you identify and correct the elevation, the faster the resolution.

Why Some People Hit These Signs at Doses That Feel Low

If you are showing two or more of these signs at a dose that others run without issue, your GHR genotype is the most likely explanation. About 25 to 50% of the population carries at least one copy of the exon-3 deleted growth hormone receptor (d3-GHR) allele. A 2009 JCEM study found that d3-allele carriers required approximately 25% less GH than full-length carriers to reach the same IGF-1 elevation.

What that means for peptide users: if you are d3/d3 homozygous, the dose that everyone in your training group runs without issue may be your individual ceiling, not your floor. Standard dosing charts are built for the median responder. You may not be the median responder. The GHR Exon 3 deletion article covers the genetics and what it means for your target dose.

The IGFBP-3 layer adds a second dimension. About 75 to 80% of circulating IGF-1 is bound to IGFBP-3 in the blood. Variants that reduce IGFBP-3 production leave more free IGF-1 available to tissues at the same total IGF-1 reading. A "normal" total IGF-1 can represent meaningfully elevated biological activity in a low-IGFBP-3 carrier. Running both IGF-1 and IGFBP-3 at the same draw gives a more complete picture. The IGF-1 to IGFBP-3 ratio guide explains how to interpret the combined result.

If you want to know your actual GHR and IGFBP-3 status before your next protocol decision, your genetic report for ipamorelin covers both variants alongside the full panel of receptor and metabolizer genes that determine your GH peptide response.